Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Assessment of the Anti-Tumor Effects of Poly(I:C) Combined with QS-21 on Melanoma Cells(B16F10)

ABSTRACT: Assessment of the Anti-Tumor Effects of Poly(I:C) Combined with QS-21 on Melanoma Cells(B16F10)

PROVIDER: PRJNA1215363 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR32119649_1.fastq.gz	Fastqsanger.gz
	SRR32119649_2.fastq.gz	Fastqsanger.gz
	SRR32119650_1.fastq.gz	Fastqsanger.gz
	SRR32119650_2.fastq.gz	Fastqsanger.gz
	SRR32119651_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Assessment of the Anti-Tumor Effects of Poly(I:C) Combined with QS-21 on Melanoma Cells(B16F10)

Project description:This study explores the synergistic antitumor potential of Poly(I:C) and QS-21 in melanoma treatment. Through in vitro assays and animal models, we evaluated their combined impact on melanoma cell proliferation, apoptosis, and immune response. Our results indicate that Poly(I:C), an immunostimulant, activates the immune system to bolster antitumor activity. QS-21, an immunological adjuvant, enhances Poly(I:C)'s effects, together acting as an in situ vaccine to expose neoantigens and reignite the tumor-immune interaction. This research offers a promising immunotherapeutic approach for melanoma.

2025-01-31 | GSE287957 | GEO

Microarray analysis of the Lysosome-dependent activation of human dendritic cells by the vaccine adjuvant QS-21.

Project description:QS-21 is a component of the Adjuvant System AS01 that is used in several vaccine candidates. QS-21 strongly potentiates both cellular and humoral immune responses to purified antigens, yet how it activates immune cells is largely unknown. Here, QS-21 (or DQ) directly activated human monocyte-derived dendritic cells (moDCs) and promoted a pro-inflammatory transcriptional program.

2017-01-30 | E-MTAB-5388 | biostudies-arrayexpress

Microarray analysis of innate immune response induced by immunization with the adjuvant QS-21 in lymph node and muscle in mice.

Project description:The goal of this study was to identify the transcriptional mechanisms involved in the activation of the immune system by QS-21, a triterpene glycoside purified from the bark of Quillaja saponaria which has adjuvant activity in vivo. Saponins represent a promising class of vaccine adjuvant. Together with the TLR4-ligand MPL, QS-21 is part of the Adjuvant System AS01, a key component of the Malaria and Zoster candidate vaccines that display demonstrated clinical efficacy. However, the mechanism of action of QS-21 in this liposomal formulation is poorly understood. Upon intra-muscular immunisation, we observed that QS-21 rapidly accumulated in CD169+ resident macrophages of the draining lymph node where it elicited a local innate immune response. Depletion of these cells abrogated QS-21-mediated innate cell recruitment to the lymph node, dendritic cell (DC) phenotypic maturation as well as the adjuvant effect on T cell and antibody responses to co-administered antigens. DCs rather than lymph node-resident macrophages were directly involved in T cell priming by QS-21 as revealed by the decrease in antigen-specific T cell response in Batf3−/− mice. Further analysis showed that the adjuvant effect of QS-21 depended on the integration of Caspase-1 and MyD88 pathways, at least in part through the local release of HMGB1. Taken together, this work unravels the key role of lymph node sentinel macrophage in controlling the adjuvant effect of a molecule proven to improve vaccine response in humans

2016-12-06 | GSE90864 | GEO

Synthesis of QS-21-based immunoadjuvants.

Project description:Three structurally defined QS-21-based immune adjuvant candidates (2a-2c) have been synthesized. Application of the two-stage activation glycosylation approach utilizing allyl glycoside building blocks improved the synthetic accessibility of the new adjuvants. The efficient synthesis and establishment of the stand-alone adjuvanticity of the examined synthetic adjuvant (2b) open the door to the pursuit of a new series of structurally defined QS-saponin-based synthetic adjuvants.

| S-EPMC3937867 | biostudies-literature

Effect of BMP2 on B16F10 melanoma cells

Project description:BMP2 treatment significantly reduces growth of B16F10 melanoma spheroids. This experiment analyses the transcriptome changes in B16F10 cells treated with or without BMP2.

2019-01-01 | GSE117074 | GEO

Expression Data from PECAM1+ and PECAM1- B16F10 Clones

Project description:We have isolated cells from the B16F10 melanoma cell line which express the vascular-selective marker PECAM1 Here we used microarrays to determine expression profile differences across the mouse genome to determine whether these cells display additional endothelial characteristics PECAM1+ and PECAM1- B16F10 clones, along with mouse endothelial cells were cultured and harvested for RNA, which was then used in an Affymetrix Mouse Gene 1.0 ST array to determine expression signatures

2014-07-19 | E-GEOD-59564 | biostudies-arrayexpress

Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine.

Project description: Not available

| S-EPMC2602848 | biostudies-literature

Combined external beam radiotherapy (photon or carbon) and 131I-MIP-1145 (benzamide) endoradiotherapy in syngeneic B16F10 mouse tumor model

Project description:Subcutaneous B16F10 tumors in the right hind limb of C57BL/6 mice were treated with 5 daily fractions of external beam radiotherapy (8 Gy photon or 5 Gy carbon per fraction), a single fraction of 13.3 MBq 131Iodine-labelled benzamide-derivative MIP-1145 intravenously or a combination of the two. Untreated tumors served as controls. Mice were sacrificed and tumor tissue collected for expression profiling 5 days after endoradiotherapy of 1 week after the last fraction of external beam radiotherapy.

2023-12-08 | E-MTAB-6514 | biostudies-arrayexpress

Expression data from Butyroside D treated B16F10 cells [2uM]

Project description:Gene expression profiling reveals a potential role of Butyroside D in melanogenesis inhibition in B16F10 cells. B16F10 cells were murine melanoma cell line, treated with 2 μM Butyroside D for 48 h. Microarray gene expression profiling was conducted for two biological replicates

2022-09-17 | GSE213492 | GEO

Expression data from Butyroside D treated B16F10 cells [0.2uM]

Project description:Gene expression profiling reveals a potential role of Butyroside D in melanogenesis inhibition in B16F10 cells. B16F10 cells were murine melanoma cell line, treated with 0.2 μM Butyroside D for 48 h. Microarray gene expression profiling was conducted for two biological replicates

2022-09-17 | GSE213491 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data